# Compare DSIP and Semax — Chai Peptide

> A side-by-side comparison of DSIP and Semax, two Cognitive & Nootropic research peptides, across mechanism, evidence base, studied route, regulatory status, and key caution.

How a sleep peptide and a focus peptide differ in mechanism, evidence quality, studied route, and what you do and do not yet know about each.

## The short version

This page lines up [DSIP](/dsip) and [Semax](/semax) on the dimensions that matter most when reading research on calm-, focus-, and sleep-oriented peptides: mechanism, evidence base, studied route of administration, regulatory standing, and the single most important caution for each. The short version: DSIP has an unresolved mechanism and inconsistent evidence, including a large non-response rate; Semax has a much better-characterized mechanism and a coherent (if mostly rodent) evidence base, plus a genuine Russian human-use history. Neither is FDA-approved for anything, and nothing here is medical advice or a recommended dose.

## The comparison matrix

| Dimension | DSIP | Semax |
| --- | --- | --- |
| Peptide class | Endogenous nonapeptide; no identified receptor, gene, or precursor after 40+ years of study | Synthetic ACTH(4-10) analog (heptapeptide) with a specific, measured brain binding site |
| Most-studied for | Sleep architecture, stress (HPA) axis, neuroendocrine secretion | Cognition, memory, mood, neuroprotection after stroke and spinal-cord injury |
| Evidence base | Small 1980s human trials plus scattered rodent/geroprotector studies; a 2006 review calls the sleep link "still unresolved" [2] | Decades of Russian rodent and some human work; recent (2025) injury-model mechanistic studies [6][7] |
| Route studied | Intravenous (clinical studies) | Intranasal |
| Regulatory status | Not approved anywhere; sold only as a research chemical | Registered prescription drug in Russia and Ukraine only; research chemical elsewhere |
| Key caution | Genuinely unknown mechanism, and roughly half of users report no effect at all | Nasal irritation, short duration, and unstudied potentiation of stimulants and antidepressants [12] |

## Mechanism

The two compounds sit at opposite poles of "how well is this understood." DSIP has no identified receptor, gene, or precursor protein despite more than forty years of research — a 2006 review summarized it as a "still unresolved riddle" [2]. What limited mechanistic threads exist are indirect: a blood-brain-barrier transporter shared with the amino acid tryptophan, and a dopamine-relay effect on growth hormone. Semax, by contrast, binds a specific, reversible, calcium-dependent site in rat brain tissue with a measured dissociation constant of 2.4 nanomolar [9], and reliably raises the neurotrophins BDNF and NGF in specific brain regions within hours of dosing [8][9]. That is a genuinely different tier of mechanistic evidence, even though both remain unapproved research chemicals.

## Most-studied application

DSIP's literature clusters around sleep and the stress-hormone (HPA) axis, plus a smaller and more contested body of animal longevity work [3][4][5]. Semax's literature clusters around cognition, mood, and neuroprotection — it has been studied in rodent models of stroke, spinal-cord injury, and memory tasks, with a consistent finding that it raises brain growth factors and shifts immune/vascular gene expression after injury [6][7][10]. The two rarely overlap in what they're actually tested for, which is part of why they anchor opposite ends of this desk's daily-rhythm framing.

## Evidence base

This is where the two genuinely separate. DSIP's human evidence is limited to a handful of small 1980s trials and short neuroendocrine experiments, and its clearest modern positive result — a 2024 engineered fusion peptide, not native DSIP — actually underscores how much the plain molecule underperforms in comparison [1][2]. Semax's evidence base is deeper and more mechanistically specific, spanning gene-expression studies, radiolabeled pharmacokinetics, specific-binding assays, and injury-model outcomes as recent as 2025 [6][8][9][11] — but it remains overwhelmingly a rodent literature, with human use concentrated in Russian and Ukrainian clinical practice rather than Western randomized trials.

## Route studied

DSIP's clinical human studies used intravenous administration [4][5], a route with no real analog in how people use it informally today. Semax's studied and clinically used route is intranasal [11], which is also how it is most commonly used outside clinical settings — meaning the studied route and the community-used route line up more closely for Semax than for DSIP.

## Regulatory and approval status

Neither compound has FDA or EMA approval. Semax is a registered prescription medicine in Russia and Ukraine for conditions including ischemic stroke and cognitive impairment; DSIP has never achieved regulatory approval anywhere, even though its International Nonproprietary Name (Emideltide) exists on paper with no approved product behind it. Outside that narrow Russian/Ukrainian niche for Semax, both are handled purely as unregulated research chemicals.

## Key caution

For DSIP, the defining caution is the combination of a genuinely unknown mechanism and a large, honestly reported non-response rate — a real chance of feeling nothing at all, alongside cited cautions about unpredictable timing and headache [2]. For Semax, the defining caution is different in character: a much better-understood but still incompletely characterized action on neurotrophin and opioid-peptide signaling, paired with unstudied potentiation of stimulants and antidepressants and the practical nuisance of nasal irritation and a short duration of effect [9][12]. Read together, the pattern is that better-characterized mechanism does not mean fewer open questions — just different ones.

---

Chai Peptide steeps peer-reviewed findings into plain language — no prescriptions, no products, just a clearer read of what has actually been studied.